20:17 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

HT-100 regulatory update

FDA granted Akashi clearance to resume clinical development of Duchenne muscular dystrophy (DMD) candidate HT-100. The company said it plans to start a new Phase IIa trial “as quickly as possible.” In January 2016, Akashi...
22:31 , Mar 22, 2017 |  BC Extra  |  Clinical News

Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100 . The company said it intends to start a new Phase IIa trial “as...
07:00 , Aug 22, 2016 |  BC Extra  |  Financial News

ABLS spinout raises $15M in series A round

Allied Minds plc (LSE:ALM) said fibrosis and autoimmune start-up ABLS II LLC raised $15 million in a series A round. ABLS II is among three companies spun out from joint venture Allied-Bristol Life Sciences LLC,...
07:00 , Jul 18, 2016 |  BC Extra  |  Company News

Management tracks

Cancer and neurology company e-Therapeutics plc (LSE:ETX) said Malcolm Young resigned as CEO and a director. The company is searching for a replacement. Gene therapy company Calimmune Inc. (Tucson, Ariz.) promoted Jeffrey Bartlett to CSO...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/20 cls Arbutus Biopharma Corp. (NASDAQ:ABUS) Chardan Capital Madhu Kumar New Sell -6% $4.08 Kumar initiated coverage with a $3.25...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015 , a biosimilar of...
01:25 , May 10, 2016 |  BC Extra  |  Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa halted

Akashi said that a patient treated with HT-100 in the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD has died. In late January, Akashi suspended dosing and...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa suspended enrollment

Akashi suspended dosing and enrollment in all cohorts of the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD after 1 patient receiving once-daily 60 ug/kg HT-100, the...